ReviewCurrent opinion in HIV and AIDS2016
Cell and gene therapy strategies to eradicate HIV reservoirs.
Review in Current opinion in HIV and AIDS, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Preclinical toxicity analyses of lentiviral vectors expressing the HIV-1 LTR-specific designer-recombinase Brec1.PloS one · 2024Article
- Role of Tunneling Nanotube-like Structures during the Early Events of HIV Infection: Novel Features of Tissue Compartmentalization and Mechanism of HIV Spread.Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Experimental Treatment of SIV-Infected Macaques via Autograft ofMolecular therapy. Methods & clinical development · 2020Article
- Strategies to eradicate HIV from infected patients: elimination of latent provirus reservoirs.Cellular and molecular life sciences : CMLS · 2019Review
- Revisiting the 'sterilising cure' terminology: a call for more patient-centred perspectives on HIV cure-related research.Journal of virus eradication · 2019Article
- Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.Molecular therapy. Methods & clinical development · 2019Review
- Viral diversity is an obligate consideration in CRISPR/Cas9 designs for targeting the HIV reservoir.BMC biology · 2018Article
- Highlights from the 8Journal of virus eradication · 2018Article
- Epigenetic regulation of HIV-1 latency: focus on polycomb group (PcG) proteins.Clinical epigenetics · 2018Review
- Tuning DNA binding affinity and cleavage specificity of an engineered gene-targeting nuclease via surface display, flow cytometry and cellular analyses.Protein engineering, design & selection : PEDS · 2017Article
- Why cure, why now?Journal of medical ethics · 2017Article
- Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.BioMed research international · 2017Review
- Disruption or Excision of Provirus as an Approach to HIV Cure.AIDS patient care and STDs · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
purpose of reviewHighly active antiretroviral treatment has dramatically improved the prognosis for people living with HIV by preventing AIDS-related morbidity and mortality through profound suppression of viral replication. However, a long-lived viral reservoir persists in latently infected cells that harbor replication-competent HIV genomes. If therapy is discontinued, latently infected memory cells inevitably reactivate and produce infectious virus, resulting in viral rebound. The reservoir is the biggest obstacle to a cure of HIV. RECENT
findingsThis review summarizes significant advances of the past year in the development of cellular and gene therapies for HIV cure. In particular, we highlight work done on suppression or disruption of HIV coreceptors, vectored delivery of antibodies and antibody-like molecules, T-cell therapies and HIV genome disruption. SUMMARY: Several recent advancements in cellular and gene therapies have emerged at the forefront of HIV cure research, potentially having broad implications for the future of HIV treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.